Mesoblast Selects Medidata’s Cloud-based Clinical Research Platform to Accelerate Cutting-edge Stem Cell Research Leading Researcher Streamlines Regenerative Medicine Trials with Medidata’s Data Capture and Management, Site Monitoring, Coding and Safety Applications Business Wire NEW YORK -- September 12, 2012 Medidata Solutions (NASDAQ: MDSO) continues to lead the market with its cloud-based clinical development platform through a new customer commitment from Mesoblast Limited, a world leader in developing biologic products for the broad field of regenerative medicine. Mesoblast will implement Medidata Rave^®, including Rave Safety Gateway and Rave Targeted SDV, and Medidata Coder™ across its clinical studies to support the development of treatments based on its proprietary adult stem cell technology. Medidata’s platform is seen as a cost-efficient solution to improve Mesoblast’s clinical trial efficiencies across multiple therapeutic areas, to effectively monitor and control risks, and to streamline trial execution to meet tight deadline goals. Medidata Rave, a leading electronic data capture (EDC) and clinical data management (CDM) solution, enables real-time visibility into clinical trial data. The flexibility of Rave allows Mesoblast to proactively adjust a trial’s data validation plan and management processes, and also apply learnings to other studies in a timely fashion to improve trial quality and efficiency. Mesoblast selected Rave for its superior user experience and comprehensive functionality. The context-sensitive, on-screen help minimizes the dependence on calling help desks and eliminates delays in entering and cleaning data. Moreover, research sites’ familiarity with Rave will help Mesoblast to expedite site initiation. Further building out the clinical trial process, Mesoblast selected Rave Targeted SDV to reduce site monitoring costs through a risk-based approach. The implementation of Rave Safety Gateway and Medidata Coder will enable Mesoblast to increase the efficiency of its safety reporting process. *“Mesoblast chose Medidata Solutions for our ability to drive improved efficiency and more effective decision making across their trials process,” said Tarek Sherif, CEO, Medidata Solutions. “We’re very excited that the Medidata Clinical Cloud is playing a key role in allowing Mesoblast to execute at the forefront of regenerative medicine research and adult stem cell technology.” Connect with Medidata: *Read our blog, Geeks Talk Clinical *Tweet this: Mesoblast selects @Medidata #cloud based #clinical platform to accelerate development of adult stem cell technology http://bit.ly/S8Vjwt *Follow us on Twitter: @Medidata *Find us on LinkedIn About Medidata Solutions Worldwide Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics. Contact: Lois Paul and Partners Susan McCarron, 617-986-5767 Susan_mccarron@lpp.com
Sulzer Confirms Merger Talks With Dresser-Rand
Mesoblast Selects Medidata’s Cloud-based Clinical Research Platform to Accelerate Cutting-edge Stem Cell Research
Press spacebar to pause and continue. Press esc to stop.